Submit a Review & Earn an Amazon Gift Card
You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!Submit Review
MLR 1023 is a selective allosteric activator of Lyn kinase (EC50 = 63 nM); displays no significant activity against a range of 47 other kinases, including other Src family kinases such as Fyn, Lck and Src kinase. Reduces blood glucose levels without affecting in vivo insulin secretion. Orally bioavailable.
MLR 1023 is also offered as part of the Tocriscreen Antiviral Library. Find out more about compound libraries available from Tocris.
|Storage||Store at +4°C|
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.
|Solvent||Max Conc. mg/mL||Max Conc. mM|
The following data is based on the product molecular weight 202.21. Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||4.95 mL||24.73 mL||49.45 mL|
|5 mM||0.99 mL||4.95 mL||9.89 mL|
|10 mM||0.49 mL||2.47 mL||4.95 mL|
|50 mM||0.1 mL||0.49 mL||0.99 mL|
References are publications that support the biological activity of the product.
Ochman et al (2012) The Lyn kinase activator MLR-1023 is a novel Ins receptor potentiator that elicits a rapid-onset and durable improvement in glucose homeostasis in animal models of type 2 diabetes. J.Pharmacol.Exp.Ther. 342 23 PMID: 22431203
Saporito et al (2012) MLR-1023 is a potent and selective allosteric activator of Lyn kinase in vitro that improves glucose tolerance in vivo. J.Pharmacol.Exp.Ther. 342 15 PMID: 22473614
If you know of a relevant reference for MLR 1023, please let us know.
Keywords: MLR 1023, MLR 1023 supplier, MLR1023, type, II, diabetes, antidiabetic, hyperglycemia, lyn, kinase, inhibitors, inhibits, selective, Src, Kinases, 4582, Tocris Bioscience
Citations are publications that use Tocris products. Selected citations for MLR 1023 include:
Iida et al (2019) Src inhibition attenuates polyglutamine-mediated neuromuscular degeneration in spinal and bulbar muscular atrophy. Nat Commun 10 4262 PMID: 31537808
Do you know of a great paper that uses MLR 1023 from Tocris? Please let us know.
There are currently no reviews for this product. Be the first to review MLR 1023 and earn rewards!
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.